JP2023533498A5 - - Google Patents
Info
- Publication number
- JP2023533498A5 JP2023533498A5 JP2022580982A JP2022580982A JP2023533498A5 JP 2023533498 A5 JP2023533498 A5 JP 2023533498A5 JP 2022580982 A JP2022580982 A JP 2022580982A JP 2022580982 A JP2022580982 A JP 2022580982A JP 2023533498 A5 JP2023533498 A5 JP 2023533498A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- hexenoyl
- ghrh
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048167P | 2020-07-05 | 2020-07-05 | |
| US63/048,167 | 2020-07-05 | ||
| PCT/CA2021/050904 WO2022006657A1 (en) | 2020-07-05 | 2021-06-30 | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533498A JP2023533498A (ja) | 2023-08-03 |
| JP2023533498A5 true JP2023533498A5 (enExample) | 2024-07-05 |
Family
ID=79553399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580982A Pending JP2023533498A (ja) | 2020-07-05 | 2021-06-30 | Ｇｈｒｈアナログの低用量医薬組成物及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230270865A1 (enExample) |
| EP (1) | EP4175661A4 (enExample) |
| JP (1) | JP2023533498A (enExample) |
| KR (1) | KR20230035600A (enExample) |
| CN (1) | CN115884783A (enExample) |
| AU (1) | AU2021306736A1 (enExample) |
| CA (1) | CA3183299A1 (enExample) |
| IL (1) | IL298991A (enExample) |
| WO (1) | WO2022006657A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003229222B2 (en) * | 2003-05-29 | 2009-11-12 | Theratechnologies Inc. | GRF analog compositions and their use |
| US20080249017A1 (en) * | 2007-04-04 | 2008-10-09 | Theratechnologies Inc. | Pharmaceutical formulations of ghrh molecules |
| US20100267636A1 (en) * | 2009-04-20 | 2010-10-21 | Theratechnologies Inc. | Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy |
| US8361964B2 (en) * | 2011-04-21 | 2013-01-29 | Theratechnologies Inc. | Growth hormone releasing factor (GRF) analogs and uses thereof |
| US8871713B2 (en) * | 2013-03-01 | 2014-10-28 | Theratechnologies Inc. | Formulations of growth hormone releasing factor (GRF) molecules with improved stability |
| US20170037105A1 (en) * | 2015-08-03 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US20200297817A1 (en) * | 2019-03-22 | 2020-09-24 | Theratechnologies Inc. | Pharmaceutical compositions of ghrh analogs and uses thereof |
| CA3037757A1 (en) * | 2019-03-22 | 2020-09-22 | Theratechnologies Inc. | Pharmaceutical compositions of ghrh analogs and uses thereof |
| EP3947426A4 (en) * | 2019-03-29 | 2023-01-04 | The General Hospital Corporation | GHRH OR ANALOGUES FOR USE IN THE TREATMENT OF HEPATIC DISEASE |
-
2021
- 2021-06-30 US US18/012,496 patent/US20230270865A1/en active Pending
- 2021-06-30 KR KR1020237003921A patent/KR20230035600A/ko active Pending
- 2021-06-30 AU AU2021306736A patent/AU2021306736A1/en active Pending
- 2021-06-30 JP JP2022580982A patent/JP2023533498A/ja active Pending
- 2021-06-30 IL IL298991A patent/IL298991A/en unknown
- 2021-06-30 CN CN202180047566.8A patent/CN115884783A/zh active Pending
- 2021-06-30 EP EP21837118.5A patent/EP4175661A4/en active Pending
- 2021-06-30 WO PCT/CA2021/050904 patent/WO2022006657A1/en not_active Ceased
- 2021-06-30 CA CA3183299A patent/CA3183299A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131596A5 (enExample) | ||
| JP2025142338A5 (enExample) | ||
| US6869939B2 (en) | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | |
| JP4334229B2 (ja) | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 | |
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| US11865180B2 (en) | Levothyroxine formulations for oral use | |
| WO2002102383A1 (fr) | Preparation de cilostazol aqueuse pour injections | |
| JP2021113206A5 (enExample) | ||
| CN101410123A (zh) | 低剂量的双氯芬酸和β－环糊精的制剂 | |
| WO2001041757A1 (en) | Cyclodextrin-containing pharmaceutical composition | |
| JP2019501191A5 (enExample) | ||
| US20070049552A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| PT1608344E (pt) | Formulações orais de cladribina | |
| JP3597239B2 (ja) | 安定な点眼剤 | |
| US6989381B2 (en) | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | |
| WO2007022165B1 (en) | Factor xa inhibitor inclusion complex with cyclodextrin | |
| ES2397126T3 (es) | Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida | |
| WO2017085696A1 (en) | Parenteral formulations of melphalan | |
| CN108712909A (zh) | 奥利万星制剂 | |
| US6828311B2 (en) | Formulation for the parenteral application of a sodium channel blocker | |
| JP4275394B2 (ja) | 注射用シロスタゾール水性製剤 | |
| JP2005520856A (ja) | 貯蔵時に安定なエプレレノン製剤 | |
| US20120190750A1 (en) | Stable ready to use injectable paracetamol formulation | |
| ES2311220T3 (es) | Uso de trioxopirimidina para el tratamiento y prevision de enfermedades inflamatorias bronquiales. | |
| JP2005527615A (ja) | ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 |